Treatment efficacy of 0.05% cyclosporine eyedrop on ocular surface changes after anti-glaucoma medication in glaucoma patients.

Not Applicable

Recruiting

Conditions: Diseases of the eye and adnexa

Registration Number: KCT0007124

Lead Sponsor: Keimyung University Dongsan Hospital

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 30

Inclusion Criteria

1) A patient with glaucoma who is 19 years of age or older and has been instilling one or more antiglaucoma eye drops bilaterally for at least one,
2) Based on the Korean dry eye treatment guidelines at the time of first enrolling, and the diagnostic criteria presented by the Dry Eye Workshop in 2007, dry eye syndrome of level 2 or higher
3) Patients who can be followed up for at least 4 months
4) Patients who accurately understands the details of the clinical trial and has written a consent form from a voluntary doctor

Exclusion Criteria

1) Level 1 and 2 mild dry eye syndrome patients
2) Those who have had hypersensitivity reactions to this drug or other drugs, or those with a history of clinically significant hypersensitivity reactions
3) Patients who are pregnant, lactating, or planning to become pregnant
4) Those who participated in other clinical trials within 3 months before the first administration date
5) If there is a history of corneal or glaucoma surgery or intraocular surgery within 6 months of screening
6) Patients who want to wear contact lenses during the clinical trial period
7) Patients with eye diseases that require treatment other than dry eye syndrome and glaucoma
8) Patients received lacrimal punctal surgery (punctal plug and surgical lacrimal closure) within 1 month before instillation